

Japan's New Fast-Track Pathway for Drugmakers

Table of Contents

Introduction

Closing the Gap..... 3

Legal and Regulatory Efforts to Speed Drug Approvals 3

Taking Advantage of the New Sakigake Pathway 6

How Can Drugmakers Qualify for Sakigake Designation? 6

Five Benefits of the Sakigake Pathway 6

A Step-by-Step Guide for Navigating the Sakigake Pathway 7

Sakigake-Designated Products Announced in 2015..... 8

What Sponsors Should Do Now 9

Other Opportunities for Accelerated Review 11

Orphan Drug Applications 11

Priority Review for Non-Orphan Drugs 12

Accelerated Review for Regenerative Medicines..... 12

The Traditional Roadmap for Drug Development in Japan 13

Preparation Phase 13

Interaction Phase..... 14

Clinical Phase..... 17

Submission Phase 18

Strategic Considerations for Japanese Drug Development..... 22

Appendices..... 23

A. Basic Principles on Global Clinical Trials

B. Strategy of Sakigake

C. Overview of Orphan Drug/Medical Device Designation System

D. Ministerial Ordinance on Good Clinical Practice for Drugs

E. Points to Be Considered by the Review Staff Involved in the Evaluation Process of New Drugs